Adhera Therapeutics Inc Quick Ratio (ATRX) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Adhera Therapeutics Inc   (ATRX)

Adhera Therapeutics Inc 's Quick Ratio

ATRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Quick Ratio deteriorated to 0 a new company low.

Within Major Pharmaceutical Preparations industry 601 other companies have achieved higher Quick Ratio than Adhera Therapeutics Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 4404 to 5554.

Explain Quick Ratio?
How much Cash & cash equivalents ATRX´s has?
What are ATRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ATRX Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 9.05 % -9.63 % 9.2 % 34.68 % 35.24 %
Y / Y Cash & cash equivalent Change -93.17 % 72.5 % -78.81 % 216.67 % 84800 %
Quick Ratio MRQ 0 0 0 0.01 0.04
ATRX's Total Ranking # 5554 # 4404 # 5590 # 5003 # 3874
Seq. Current Liabilities Change -1.41 % 4.19 % 0.92 % 5.21 % -18.3 %
Seq. Cash & cash equivalent Change -15.94 % 115.63 % -75.94 % -84.33 % 2022.5 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 602
Healthcare Sector # 1203
Overall Market # 5554


Quick Ratio Statistics
High Average Low
0.04 0.01 0
(Jun 30 2022)   (Mar 31 2021)




Financial Statements
Adhera Therapeutics Inc 's Current Liabilities $ 23 Millions Visit ATRX's Balance sheet
Adhera Therapeutics Inc 's Cash & cash equivalent $ 0 Millions Visit ATRX's Balance sheet
Source of ATRX's Sales Visit ATRX's Sales by Geography


Cumulative Adhera Therapeutics Inc 's Quick Ratio

ATRX's Quick Ratio for the trailling 12 Months

ATRX Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 8.37 % 13.54 % 74.01 % 179.39 % 437.93 %
Y / Y Cash & cash equivalent TTM Growth -73.01 % 362.82 % 443.3 % 2627.91 % 108100 %
Quick Ratio TTM 0 0.01 0.01 0.01 0.01
Total Ranking TTM # 4304 # 4299 # 4200 # 3766 # 4285
Seq. Current Liabilities TTM Growth 2.14 % -2.72 % 2.1 % 6.81 % 7.01 %
Seq. Cash & cash equivalent TTM Growth -73.04 % 2.75 % -10.14 % 8.41 % 362.39 %

Quick ratio ranking by company, industry and sector >> Back to ATRX Financial Strength Comparisons >> Go to Compare ATRX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q2 2023 to $22.87 millions, cumulative Quick Ratio decreased to 0 below the Adhera Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 561 other companies have achieved higher Quick Ratio than Adhera Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 4299 to 4304.

Explain Quick Ratio?
How much Cash & cash equivalents ATRX´s has?
What are ATRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 562
Healthcare Sector # 1129
Within the Market # 4304


trailing twelve months Quick Ratio Statistics
High Average Low
0.01 0.01 0
(Sep 30 2022)   (Sep 30 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Cell Source Inc   0.01 $ 0.022  Millions$ 3.692  Millions
Biostax Corp  0.01 $ 0.023  Millions$ 3.861  Millions
Propanc Biopharma Inc 0.00 $ 0.010  Millions$ 3.158  Millions
Adhera Therapeutics Inc 0.00 $ 0.058  Millions$ 22.869  Millions
REST EZ Inc. 0.00 $ 0.000  Millions$ 0.042  Millions
Actavia Life Sciences Inc 0.00 $ 0.002  Millions$ 1.697  Millions
Skinvisible Inc 0.00 $ 0.004  Millions$ 2.980  Millions
Aridis Pharmaceuticals Inc 0.00 $ 0.019  Millions$ 20.394  Millions
Theralink Technologies Inc 0.00 $ 0.045  Millions$ 48.081  Millions
Rebus Holdings Inc 0.00 $ 0.005  Millions$ 5.619  Millions
60 Degrees Pharmaceuticals Inc 0.00 $ 0.019  Millions$ 28.863  Millions
Respirerx Pharmaceuticals Inc 0.00 $ 0.007  Millions$ 12.210  Millions

Date modified: 2026-09-08T15:11:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.